In the last 12 months, insiders at VERACYTE, INC. ($VCYT) filed 311 transactions with the SEC: 0 open-market purchases totaling $0 and 115 sales totaling $28,609,930. Net insider sentiment: net selling.
VERACYTE, INC. operates in the Services-medical laboratories industry (Industrial Applications and Services sector).
Most Active Insiders
- Stapley Marc (Chief Executive Officer) — 34 transactions totaling $10,442,469
- JONES EVAN/ FA (Director) — 45 transactions totaling $6,482,871
- Anderson Bonnie H (Director) — 15 transactions totaling $5,739,057
- Chambers Rebecca (Chief Financial Officer) — 33 transactions totaling $5,229,415
- EASTHAM KARIN (Director) — 33 transactions totaling $4,314,046
View all SEC Filings for VERACYTE, INC. (VCYT).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| March 6, 2026 | Leite John | Chief Commercial Officer-CLIA | A | Common Stock | 36181 | $0.00 | 143,761.0000 | 79,946,386 | 33.63% | 0.05% |
| March 6, 2026 | Leite John | Chief Commercial Officer-CLIA | A | Common Stock | 6578 | $0.00 | 150,339.0000 | 79,946,386 | 4.58% | 0.01% |
| March 6, 2026 | Chambers Rebecca | Chief Financial Officer | A | Common Stock | 13157 | $0.00 | 180,534.0000 | 79,946,386 | 7.86% | 0.02% |
| March 6, 2026 | Chambers Rebecca | Chief Financial Officer | A | Common Stock | 36181 | $0.00 | 167,377.0000 | 79,946,386 | 27.58% | 0.05% |
| March 6, 2026 | Stapley Marc | Chief Executive Officer | A | Common Stock | 92099 | $0.00 | 449,653.0000 | 79,946,386 | 25.76% | 0.12% |
| March 6, 2026 | Wygant Jonathan | VP, Chief Accounting Officer | A | Common Stock | 10525 | $0.00 | 45,434.0000 | 79,946,386 | 30.15% | 0.01% |
| March 6, 2026 | McGuire Annie | SVP, General Counsel | A | Common Stock | 32892 | $0.00 | 127,598.0000 | 79,946,386 | 34.73% | 0.04% |
| March 6, 2026 | McGuire Annie | SVP, General Counsel | A | Common Stock | 26314 | $0.00 | 153,912.0000 | 79,946,386 | 20.62% | 0.03% |
| March 6, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | A | Common Stock | 29603 | $0.00 | 146,949.0000 | 79,946,386 | 25.23% | 0.04% |
| March 6, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | A | Common Stock | 6578 | $0.00 | 153,527.0000 | 79,946,386 | 4.48% | 0.01% |
| March 4, 2026 | Stapley Marc | Chief Executive Officer | S | Common Stock | 19244 | $35.56 | 383,833.0000 | 79,946,386 | 4.77% | 0.02% |
| March 4, 2026 | Leite John | Chief Commercial Officer-CLIA | S | Common Stock | 5260 | $35.19 | 107,580.0000 | 79,946,386 | 4.66% | 0.01% |
| March 4, 2026 | McGuire Annie | SVP, General Counsel | S | Common Stock | 4994 | $35.29 | 96,370.0000 | 79,946,386 | 4.93% | 0.01% |
| March 4, 2026 | McGuire Annie | SVP, General Counsel | S | Common Stock | 1664 | $36.34 | 94,706.0000 | 79,946,386 | 1.73% | 0.00% |
| March 4, 2026 | Chambers Rebecca | Chief Financial Officer | S | Common Stock | 4400 | $35.55 | 145,137.0000 | 79,946,386 | 2.94% | 0.01% |
| March 4, 2026 | Chambers Rebecca | Chief Financial Officer | S | Common Stock | 13941 | $36.33 | 131,196.0000 | 79,946,386 | 9.61% | 0.02% |
| March 4, 2026 | Stapley Marc | Chief Executive Officer | S | Common Stock | 26279 | $36.28 | 357,554.0000 | 79,946,386 | 6.85% | 0.03% |
| March 2, 2026 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 7234 | $36.01 | 149,537.0000 | 79,946,386 | 4.61% | 0.01% |
| March 2, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | S | Common Stock | 13425 | $36.16 | 117,346.0000 | 79,946,386 | 10.27% | 0.02% |
| March 2, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | F | Common Stock | 6035 | $36.01 | 130,771.0000 | 79,946,386 | 4.41% | 0.01% |
| March 2, 2026 | McGuire Annie | SVP, General Counsel | F | Common Stock | 6902 | $36.01 | 101,364.0000 | 79,946,386 | 6.38% | 0.01% |
| March 2, 2026 | Wygant Jonathan | VP, Chief Accounting Officer | F | Common Stock | 3006 | $36.01 | 34,909.0000 | 79,946,386 | 7.93% | 0.00% |
| March 2, 2026 | Leite John | Chief Commercial Officer-CLIA | F | Common Stock | 7517 | $36.01 | 112,840.0000 | 79,946,386 | 6.25% | 0.01% |
| March 2, 2026 | Stapley Marc | Chief Executive Officer | F | Common Stock | 19455 | $36.01 | 403,077.0000 | 79,946,386 | 4.60% | 0.02% |
| Feb. 26, 2026 | Stapley Marc | Chief Executive Officer | A | Common Stock | 139074 | $0.00 | 458,373.0000 | 79,946,386 | 43.56% | 0.17% |
| Feb. 26, 2026 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 12049 | $38.75 | 156,771.0000 | 79,946,386 | 7.14% | 0.02% |
| Feb. 26, 2026 | Stapley Marc | Chief Executive Officer | F | Common Stock | 35841 | $38.75 | 422,532.0000 | 79,946,386 | 7.82% | 0.04% |
| Feb. 26, 2026 | Chambers Rebecca | Chief Financial Officer | A | Common Stock | 59324 | $0.00 | 168,820.0000 | 79,946,386 | 54.18% | 0.07% |
| Feb. 26, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | A | Common Stock | 71806 | $0.00 | 161,292.0000 | 79,946,386 | 80.24% | 0.09% |
| Feb. 26, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | F | Common Stock | 24486 | $38.75 | 136,806.0000 | 79,946,386 | 15.18% | 0.03% |
| Feb. 26, 2026 | McGuire Annie | SVP, General Counsel | A | Common Stock | 50999 | $0.00 | 119,133.0000 | 79,946,386 | 74.85% | 0.06% |
| Feb. 26, 2026 | McGuire Annie | SVP, General Counsel | F | Common Stock | 10867 | $38.75 | 108,266.0000 | 79,946,386 | 9.12% | 0.01% |
| Feb. 26, 2026 | Leite John | Chief Commercial Officer-CLIA | A | Common Stock | 47149 | $0.00 | 129,262.0000 | 79,946,386 | 57.42% | 0.06% |
| Feb. 26, 2026 | Leite John | Chief Commercial Officer-CLIA | F | Common Stock | 8905 | $38.75 | 120,357.0000 | 79,946,386 | 6.89% | 0.01% |
| Dec. 16, 2025 | McGuire Annie | SVP, General Counsel | S | Common Stock | 100 | $43.68 | 67,760.0000 | 79,946,386 | 0.15% | 0.00% |
| Dec. 16, 2025 | McGuire Annie | SVP, General Counsel | S | Common Stock | 10639 | $43.13 | 67,860.0000 | 79,946,386 | 13.55% | 0.01% |
| Dec. 5, 2025 | EASTHAM KARIN | Director | M | Stock Option (right to buy) | 10000 | $0.00 | 0.0000 | 79,946,386 | 100.00% | 0.01% |
| Dec. 5, 2025 | EASTHAM KARIN | Director | M | Stock Option (right to buy) | 10000 | $0.00 | 0.0000 | 79,946,386 | 100.00% | 0.01% |
| Dec. 5, 2025 | EASTHAM KARIN | Director | M | Common Stock | 10000 | $7.94 | 23,554.0000 | 79,946,386 | 73.78% | 0.01% |
| Dec. 5, 2025 | EASTHAM KARIN | Director | M | Common Stock | 10000 | $7.60 | 33,554.0000 | 79,946,386 | 42.46% | 0.01% |
| Dec. 5, 2025 | EASTHAM KARIN | Director | S | Common Stock | 6392 | $44.52 | 27,162.0000 | 79,946,386 | 19.05% | 0.01% |
| Dec. 5, 2025 | EASTHAM KARIN | Director | S | Common Stock | 12808 | $45.84 | 14,354.0000 | 79,946,386 | 47.15% | 0.02% |
| Dec. 5, 2025 | EASTHAM KARIN | Director | S | Common Stock | 800 | $46.59 | 13,554.0000 | 79,946,386 | 5.57% | 0.00% |
| Dec. 2, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | F | Common Stock | 2955 | $46.16 | 89,486.0000 | 79,946,386 | 3.20% | 0.00% |
| Dec. 2, 2025 | Stapley Marc | Chief Executive Officer | F | Common Stock | 7914 | $46.16 | 326,271.0000 | 79,946,386 | 2.37% | 0.01% |
| Dec. 2, 2025 | McGuire Annie | SVP, General Counsel | F | Common Stock | 3052 | $46.16 | 79,921.0000 | 79,946,386 | 3.68% | 0.00% |
| Dec. 4, 2025 | McGuire Annie | SVP, General Counsel | S | Common Stock | 720 | $47.10 | 79,201.0000 | 79,946,386 | 0.90% | 0.00% |
| Dec. 4, 2025 | Chambers Rebecca | Chief Financial Officer | S | Common Stock | 4741 | $47.25 | 109,496.0000 | 79,946,386 | 4.15% | 0.01% |
| Dec. 4, 2025 | McGuire Annie | SVP, General Counsel | S | Common Stock | 702 | $47.51 | 78,499.0000 | 79,946,386 | 0.89% | 0.00% |
| Dec. 2, 2025 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 3384 | $46.16 | 122,774.0000 | 79,946,386 | 2.68% | 0.00% |
| Dec. 4, 2025 | Chambers Rebecca | Chief Financial Officer | S | Common Stock | 8537 | $46.61 | 114,237.0000 | 79,946,386 | 6.95% | 0.01% |
| Dec. 2, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | F | Common Stock | 1325 | $46.16 | 37,420.0000 | 79,946,386 | 3.42% | 0.00% |
| Dec. 4, 2025 | Leite John | Chief Commercial Officer-CLIA | S | Common Stock | 1278 | $47.51 | 82,113.0000 | 79,946,386 | 1.53% | 0.00% |
| Dec. 2, 2025 | Leite John | Chief Commercial Officer-CLIA | F | Common Stock | 2900 | $46.16 | 83,391.0000 | 79,946,386 | 3.36% | 0.00% |
| Dec. 4, 2025 | Stapley Marc | Chief Executive Officer | S | Common Stock | 3220 | $47.35 | 318,603.0000 | 79,946,386 | 1.00% | 0.00% |
| Dec. 4, 2025 | Stapley Marc | Chief Executive Officer | S | Common Stock | 4448 | $46.90 | 321,823.0000 | 79,946,386 | 1.36% | 0.01% |
| Nov. 25, 2025 | JONES EVAN/ FA | Director | S | Common Stock | 1106 | $50.25 | 29,362.0000 | 79,946,386 | 3.63% | 0.00% |
| Nov. 25, 2025 | Leite John | Chief Commercial Officer-CLIA | S | Common Stock | 2808 | $50.00 | 86,291.0000 | 79,946,386 | 3.15% | 0.00% |
| Nov. 20, 2025 | Holstein Jens | Director | S | Common Stock | 7049 | $42.48 | 28,659.0000 | 79,946,386 | 19.74% | 0.01% |
| Nov. 20, 2025 | Holstein Jens | Director | S | Common Stock | 1460 | $43.21 | 27,199.0000 | 79,946,386 | 5.09% | 0.00% |
| Nov. 20, 2025 | Holstein Jens | Director | S | Common Stock | 1491 | $40.95 | 35,708.0000 | 79,946,386 | 4.01% | 0.00% |
| Nov. 10, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | S | Common Stock | 5102 | $42.33 | 38,745.0000 | 79,946,386 | 11.64% | 0.01% |
| Nov. 7, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | S | Common Stock | 5818 | $40.21 | 43,847.0000 | 79,946,386 | 11.71% | 0.01% |
| Nov. 5, 2025 | EASTHAM KARIN | Director | S | Common Stock | 9674 | $40.02 | 13,554.0000 | 79,946,386 | 41.65% | 0.01% |
| Nov. 5, 2025 | Chambers Rebecca | Chief Financial Officer | S | Common Stock | 7000 | $41.00 | 126,158.0000 | 79,946,386 | 5.26% | 0.01% |
| Nov. 5, 2025 | JONES EVAN/ FA | Director | M | Stock Option (right to buy) | 10000 | $0.00 | 0.0000 | 79,946,386 | 100.00% | 0.01% |
| Nov. 5, 2025 | JONES EVAN/ FA | Director | M | Stock Option (right to buy) | 10000 | $0.00 | 0.0000 | 79,946,386 | 100.00% | 0.01% |
| Nov. 5, 2025 | JONES EVAN/ FA | Director | M | Stock Option (right to buy) | 10000 | $0.00 | 0.0000 | 79,946,386 | 100.00% | 0.01% |
| Nov. 5, 2025 | JONES EVAN/ FA | Director | S | Common Stock | 657 | $46.38 | 30,468.0000 | 79,946,386 | 2.11% | 0.00% |
| Nov. 5, 2025 | JONES EVAN/ FA | Director | S | Common Stock | 24296 | $45.73 | 31,125.0000 | 79,946,386 | 43.84% | 0.03% |
| Nov. 5, 2025 | JONES EVAN/ FA | Director | S | Common Stock | 5872 | $45.07 | 55,421.0000 | 79,946,386 | 9.58% | 0.01% |
| Nov. 5, 2025 | JONES EVAN/ FA | Director | S | Common Stock | 10837 | $43.80 | 61,293.0000 | 79,946,386 | 15.02% | 0.01% |
| Nov. 5, 2025 | JONES EVAN/ FA | Director | S | Common Stock | 1126 | $43.03 | 72,130.0000 | 79,946,386 | 1.54% | 0.00% |
| Nov. 5, 2025 | JONES EVAN/ FA | Director | S | Common Stock | 408 | $41.74 | 73,256.0000 | 79,946,386 | 0.55% | 0.00% |
| Nov. 5, 2025 | JONES EVAN/ FA | Director | M | Common Stock | 10000 | $7.60 | 73,664.0000 | 79,946,386 | 15.71% | 0.01% |
| Nov. 5, 2025 | JONES EVAN/ FA | Director | M | Common Stock | 10000 | $7.94 | 63,664.0000 | 79,946,386 | 18.63% | 0.01% |
| Nov. 5, 2025 | JONES EVAN/ FA | Director | M | Common Stock | 10000 | $5.28 | 53,664.0000 | 79,946,386 | 22.90% | 0.01% |
| Nov. 5, 2025 | McGuire Annie | SVP, General Counsel | S | Common Stock | 6466 | $40.00 | 82,973.0000 | 79,946,386 | 7.23% | 0.01% |
| Oct. 28, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | A | Common Stock | 2886 | $0.00 | 49,665.0000 | 79,946,386 | 6.17% | 0.00% |
| Oct. 6, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | S | Common Stock | 8349 | $36.02 | 92,441.0000 | 79,946,386 | 8.28% | 0.01% |
| Oct. 1, 2025 | Leite John | Chief Commercial Officer-CLIA | S | Common Stock | 2539 | $35.00 | 89,099.0000 | 79,946,386 | 2.77% | 0.00% |
| Oct. 1, 2025 | EPSTEIN ROBERT S | Director | M | Common Stock | 10000 | $7.94 | 83,919.0000 | 79,946,386 | 13.53% | 0.01% |
| Oct. 1, 2025 | EPSTEIN ROBERT S | Director | S | Common Stock | 21473 | $35.08 | 62,446.0000 | 79,946,386 | 25.59% | 0.03% |
| Oct. 1, 2025 | EPSTEIN ROBERT S | Director | M | Stock Option (right to buy) | 10000 | $0.00 | 0.0000 | 79,946,386 | 100.00% | 0.01% |
| Oct. 1, 2025 | McGuire Annie | SVP, General Counsel | S | Common Stock | 2160 | $35.00 | 89,439.0000 | 79,946,386 | 2.36% | 0.00% |
| Sept. 19, 2025 | McGuire Annie | SVP, General Counsel | S | Common Stock | 2283 | $33.69 | 91,599.0000 | 78,163,217 | 2.43% | 0.00% |
| Sept. 4, 2025 | Stapley Marc | Chief Executive Officer | S | Common Stock | 7667 | $30.41 | 334,185.0000 | 78,163,217 | 2.24% | 0.01% |
| Sept. 2, 2025 | Stapley Marc | Chief Executive Officer | F | Common Stock | 7914 | $30.11 | 341,852.0000 | 78,163,217 | 2.26% | 0.01% |
| Sept. 2, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | F | Common Stock | 2955 | $30.11 | 100,790.0000 | 78,163,217 | 2.85% | 0.00% |
| Sept. 2, 2025 | Leite John | Chief Commercial Officer-CLIA | F | Common Stock | 2902 | $30.11 | 91,638.0000 | 78,163,217 | 3.07% | 0.00% |
| Sept. 2, 2025 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 5371 | $30.11 | 133,158.0000 | 78,163,217 | 3.88% | 0.01% |
| Sept. 2, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | F | Common Stock | 1648 | $30.11 | 46,779.0000 | 78,163,217 | 3.40% | 0.00% |
| Sept. 2, 2025 | McGuire Annie | SVP, General Counsel | F | Common Stock | 3507 | $30.11 | 93,882.0000 | 78,163,217 | 3.60% | 0.00% |
| June 18, 2025 | JONES EVAN/ FA | Director | A | Common Stock | 9321 | $0.00 | 43,664.0000 | 78,163,217 | 27.14% | 0.01% |
| June 18, 2025 | Barr Eliav | Director | A | Common Stock | 9321 | $0.00 | 51,189.0000 | 78,163,217 | 22.26% | 0.01% |
| June 18, 2025 | EPSTEIN ROBERT S | Director | A | Common Stock | 9321 | $0.00 | 73,919.0000 | 78,163,217 | 14.43% | 0.01% |
| June 18, 2025 | EASTHAM KARIN | Director | A | Common Stock | 9321 | $0.00 | 23,228.0000 | 78,163,217 | 67.02% | 0.01% |
| June 18, 2025 | Holstein Jens | Director | A | Common Stock | 9321 | $0.00 | 37,199.0000 | 78,163,217 | 33.43% | 0.01% |
| June 18, 2025 | Shafer David Brent | Director | A | Common Stock | 9321 | $0.00 | 25,828.0000 | 78,163,217 | 56.47% | 0.01% |
| June 18, 2025 | Miller Thomas F. | Director | A | Common Stock | 9321 | $0.00 | 25,828.0000 | 78,163,217 | 56.47% | 0.01% |
| June 18, 2025 | Bhanji Muna | Director | A | Common Stock | 9321 | $0.00 | 39,310.0000 | 78,163,217 | 31.08% | 0.01% |
| June 13, 2025 | Bhanji Muna | Director | S | Common Stock | 4589 | $26.67 | 29,989.0000 | 78,163,217 | 13.27% | 0.01% |
| June 13, 2025 | EASTHAM KARIN | Director | S | Common Stock | 4590 | $26.66 | 13,907.0000 | 78,163,217 | 24.81% | 0.01% |
| June 4, 2025 | Leite John | Chief Commercial Officer-CLIA | S | Common Stock | 2809 | $27.20 | 94,540.0000 | 78,163,217 | 2.89% | 0.00% |
| June 2, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | F | Common Stock | 2955 | $26.74 | 103,745.0000 | 78,163,217 | 2.77% | 0.00% |
| June 2, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | F | Common Stock | 1848 | $26.74 | 47,915.0000 | 78,163,217 | 3.71% | 0.00% |
| June 2, 2025 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 5370 | $26.74 | 138,529.0000 | 78,163,217 | 3.73% | 0.01% |
| June 2, 2025 | Leite John | Chief Commercial Officer-CLIA | F | Common Stock | 2900 | $26.74 | 97,349.0000 | 78,163,217 | 2.89% | 0.00% |
| June 2, 2025 | McGuire Annie | SVP, General Counsel | F | Common Stock | 3505 | $26.74 | 97,003.0000 | 78,163,217 | 3.49% | 0.00% |
| June 2, 2025 | Stapley Marc | Chief Executive Officer | F | Common Stock | 9399 | $26.74 | 349,237.0000 | 78,163,217 | 2.62% | 0.01% |
| March 6, 2025 | Leite John | Chief Commercial Officer-CLIA | A | Common Stock | 36240 | $0.00 | 107,660.0000 | 78,163,217 | 50.74% | 0.05% |
| March 6, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | A | Common Stock | 13288 | $0.00 | 49,763.0000 | 78,163,217 | 36.43% | 0.02% |
| March 6, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | A | Common Stock | 24160 | $0.00 | 106,700.0000 | 78,163,217 | 29.27% | 0.03% |
| March 6, 2025 | Chambers Rebecca | Chief Financial Officer | A | Common Stock | 30200 | $0.00 | 143,899.0000 | 78,163,217 | 26.56% | 0.04% |
| March 7, 2025 | Leite John | Chief Commercial Officer-CLIA | S | Common Stock | 2400 | $31.04 | 105,260.0000 | 78,163,217 | 2.23% | 0.00% |
| March 7, 2025 | Leite John | Chief Commercial Officer-CLIA | S | Common Stock | 5011 | $31.96 | 100,249.0000 | 78,163,217 | 4.76% | 0.01% |
| March 6, 2025 | McGuire Annie | SVP, General Counsel | A | Common Stock | 30200 | $0.00 | 100,508.0000 | 78,163,217 | 42.95% | 0.04% |
| March 6, 2025 | Stapley Marc | Chief Executive Officer | A | Common Stock | 90601 | $0.00 | 358,636.0000 | 78,163,217 | 33.80% | 0.12% |
| March 4, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | S | Common Stock | 3570 | $33.95 | 82,540.0000 | 78,163,217 | 4.15% | 0.00% |
| March 4, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | S | Common Stock | 4467 | $32.86 | 86,110.0000 | 78,163,217 | 4.93% | 0.01% |
| March 4, 2025 | McGuire Annie | SVP, General Counsel | S | Common Stock | 1142 | $33.69 | 70,308.0000 | 78,163,217 | 1.60% | 0.00% |
| March 4, 2025 | Stapley Marc | Chief Executive Officer | S | Common Stock | 1094 | $34.37 | 268,035.0000 | 78,163,217 | 0.41% | 0.00% |
| March 4, 2025 | Stapley Marc | Chief Executive Officer | S | Common Stock | 23414 | $33.91 | 269,129.0000 | 78,163,217 | 8.00% | 0.03% |
| March 4, 2025 | Stapley Marc | Chief Executive Officer | S | Common Stock | 28189 | $32.82 | 292,543.0000 | 78,163,217 | 8.79% | 0.04% |
| March 2, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | F | Common Stock | 4301 | $34.76 | 36,475.0000 | 78,163,217 | 10.55% | 0.01% |
| Feb. 27, 2025 | Leite John | Chief Commercial Officer-CLIA | S | Common Stock | 5746 | $33.84 | 79,070.0000 | 78,163,217 | 6.77% | 0.01% |
| March 2, 2025 | Stapley Marc | Chief Executive Officer | F | Common Stock | 20324 | $34.76 | 320,732.0000 | 78,163,217 | 5.96% | 0.03% |
| Feb. 27, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | A | Common Stock | 30589 | $0.00 | 113,003.0000 | 78,163,217 | 37.12% | 0.04% |
| Feb. 27, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | F | Common Stock | 15672 | $33.84 | 97,331.0000 | 78,163,217 | 13.87% | 0.02% |
| March 2, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | F | Common Stock | 6754 | $34.76 | 90,577.0000 | 78,163,217 | 6.94% | 0.01% |
| Feb. 27, 2025 | Leite John | Chief Commercial Officer-CLIA | A | Common Stock | 11006 | $0.00 | 84,816.0000 | 78,163,217 | 14.91% | 0.01% |
| Feb. 27, 2025 | Chambers Rebecca | Chief Financial Officer | A | Common Stock | 23170 | $0.00 | 136,680.0000 | 78,163,217 | 20.41% | 0.03% |
| Feb. 27, 2025 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 11911 | $33.84 | 124,769.0000 | 78,163,217 | 8.71% | 0.02% |
| March 2, 2025 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 11070 | $34.76 | 113,699.0000 | 78,163,217 | 8.87% | 0.01% |
| Feb. 27, 2025 | McGuire Annie | SVP, General Counsel | A | Common Stock | 13466 | $0.00 | 86,705.0000 | 78,163,217 | 18.39% | 0.02% |
| Feb. 27, 2025 | McGuire Annie | SVP, General Counsel | F | Common Stock | 7000 | $33.84 | 79,705.0000 | 78,163,217 | 8.07% | 0.01% |
| March 2, 2025 | McGuire Annie | SVP, General Counsel | F | Common Stock | 8255 | $34.76 | 71,450.0000 | 78,163,217 | 10.36% | 0.01% |
| March 2, 2025 | Leite John | Chief Commercial Officer-CLIA | F | Common Stock | 7650 | $34.76 | 71,420.0000 | 78,163,217 | 9.67% | 0.01% |
| Feb. 27, 2025 | Stapley Marc | Chief Executive Officer | A | Common Stock | 67277 | $0.00 | 375,329.0000 | 78,163,217 | 21.84% | 0.09% |
| Feb. 27, 2025 | Stapley Marc | Chief Executive Officer | F | Common Stock | 34273 | $33.84 | 341,056.0000 | 78,163,217 | 9.13% | 0.04% |
| Feb. 3, 2025 | Chambers Rebecca | Chief Financial Officer | S | Common Stock | 527 | $43.85 | 113,510.0000 | 78,163,217 | 0.46% | 0.00% |
| Jan. 6, 2025 | EPSTEIN ROBERT S | Director | M | Stock Option (right to buy) | 20000 | $0.00 | 0.0000 | 78,163,217 | 100.00% | 0.03% |
| Jan. 6, 2025 | EPSTEIN ROBERT S | Director | M | Common Stock | 20000 | $8.04 | 64,598.0000 | 78,163,217 | 44.85% | 0.03% |
| Jan. 2, 2025 | EASTHAM KARIN | Director | S | Common Stock | 4691 | $40.50 | 18,497.0000 | 78,163,217 | 20.23% | 0.01% |
| Jan. 2, 2025 | EASTHAM KARIN | Director | S | Common Stock | 5309 | $40.12 | 23,188.0000 | 78,163,217 | 18.63% | 0.01% |
| Jan. 2, 2025 | EASTHAM KARIN | Director | M | Common Stock | 10000 | $5.28 | 28,497.0000 | 78,163,217 | 54.06% | 0.01% |
| Jan. 2, 2025 | EASTHAM KARIN | Director | M | Stock Option (right to buy) | 10000 | $0.00 | 0.0000 | 78,163,217 | 100.00% | 0.01% |
| Dec. 13, 2024 | Stapley Marc | Chief Executive Officer | S | Common Stock | 400 | $44.14 | 307,345.0000 | 78,465,000 | 0.13% | 0.00% |
| Dec. 13, 2024 | Stapley Marc | Chief Executive Officer | S | Common Stock | 5190 | $43.37 | 307,745.0000 | 78,465,000 | 1.66% | 0.01% |
| Dec. 4, 2024 | McGuire Annie | SVP, General Counsel | S | Common Stock | 18699 | $44.02 | 72,869.0000 | 78,465,000 | 20.42% | 0.02% |
| Dec. 4, 2024 | Febbo Phillip G. | Chief Scientific & Med Officer | S | Common Stock | 3934 | $44.09 | 82,414.0000 | 78,465,000 | 4.56% | 0.01% |
| Dec. 2, 2024 | Leite John | Chief Commercial Officer-CLIA | F | Common Stock | 1314 | $44.12 | 74,860.0000 | 78,465,000 | 1.72% | 0.00% |
| Dec. 2, 2024 | Stapley Marc | Chief Executive Officer | F | Common Stock | 5748 | $44.12 | 312,935.0000 | 78,465,000 | 1.80% | 0.01% |
| Dec. 3, 2024 | Wygant Jonathan | VP, Chief Accounting Officer | S | Common Stock | 956 | $43.36 | 40,270.0000 | 78,465,000 | 2.32% | 0.00% |
| Dec. 2, 2024 | Wygant Jonathan | VP, Chief Accounting Officer | F | Common Stock | 1087 | $44.12 | 41,226.0000 | 78,465,000 | 2.57% | 0.00% |
| Dec. 2, 2024 | Febbo Phillip G. | Chief Scientific & Med Officer | F | Common Stock | 6738 | $44.12 | 86,348.0000 | 78,465,000 | 7.24% | 0.01% |
| Dec. 3, 2024 | Chambers Rebecca | Chief Financial Officer | S | Common Stock | 7000 | $43.23 | 114,037.0000 | 78,465,000 | 5.78% | 0.01% |
| Dec. 2, 2024 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 3464 | $44.12 | 121,037.0000 | 78,465,000 | 2.78% | 0.00% |
| Dec. 3, 2024 | Leite John | Chief Commercial Officer-CLIA | S | Common Stock | 1050 | $43.25 | 73,810.0000 | 78,465,000 | 1.40% | 0.00% |
| Dec. 2, 2024 | McGuire Annie | SVP, General Counsel | F | Common Stock | 1918 | $44.12 | 91,568.0000 | 78,465,000 | 2.05% | 0.00% |
| Nov. 27, 2024 | Wygant Jonathan | VP, Chief Accounting Officer | S | Common Stock | 5032 | $42.89 | 42,313.0000 | 78,465,000 | 10.63% | 0.01% |
| Nov. 19, 2024 | EASTHAM KARIN | Director | S | Common Stock | 1600 | $36.77 | 31,628.0000 | 78,465,000 | 4.82% | 0.00% |
| Nov. 19, 2024 | EASTHAM KARIN | Director | S | Common Stock | 10125 | $38.76 | 18,497.0000 | 78,465,000 | 35.37% | 0.01% |
| Nov. 19, 2024 | EASTHAM KARIN | Director | S | Common Stock | 3006 | $37.77 | 28,622.0000 | 78,465,000 | 9.50% | 0.00% |
| Nov. 12, 2024 | Chambers Rebecca | Chief Financial Officer | S | Common Stock | 15275 | $38.34 | 124,501.0000 | 78,465,000 | 10.93% | 0.02% |
| Nov. 12, 2024 | EPSTEIN ROBERT S | Director | M | Common Stock | 15000 | $8.04 | 59,598.0000 | 78,465,000 | 33.63% | 0.02% |
| Nov. 12, 2024 | EPSTEIN ROBERT S | Director | S | Common Stock | 15000 | $38.32 | 44,598.0000 | 78,465,000 | 25.17% | 0.02% |
| Nov. 12, 2024 | EPSTEIN ROBERT S | Director | M | Stock Option (right to buy) | 15000 | $0.00 | 20,000.0000 | 78,465,000 | 42.86% | 0.02% |
| Sept. 19, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 5173 | $35.23 | 34,343.0000 | 72,644,487 | 13.09% | 0.01% |
| Sept. 4, 2024 | Leite John | Chief Commercial Officer-CLIA | S | Common Stock | 5479 | $29.78 | 76,174.0000 | 72,644,487 | 6.71% | 0.01% |
| Sept. 2, 2024 | Stapley Marc | Chief Executive Officer | F | Common Stock | 5748 | $31.55 | 318,683.0000 | 72,644,487 | 1.77% | 0.01% |
| Sept. 2, 2024 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 3464 | $31.55 | 139,776.0000 | 72,644,487 | 2.42% | 0.00% |
| Sept. 2, 2024 | McGuire Annie | SVP, General Counsel | F | Common Stock | 1920 | $31.55 | 93,486.0000 | 72,644,487 | 2.01% | 0.00% |
| Sept. 2, 2024 | Wygant Jonathan | VP, Chief Accounting Officer | F | Common Stock | 1087 | $31.55 | 47,345.0000 | 72,644,487 | 2.24% | 0.00% |
| Sept. 2, 2024 | Leite John | Chief Commercial Officer-CLIA | F | Common Stock | 1315 | $31.55 | 81,653.0000 | 72,644,487 | 1.58% | 0.00% |
| Sept. 3, 2024 | Miller Thomas F. | Director | A | Common Stock | 16507 | $0.00 | 16,507.0000 | 72,644,487 | 9999.99% | 0.02% |
| Sept. 3, 2024 | Shafer David Brent | Director | A | Common Stock | 16507 | $0.00 | 16,507.0000 | 72,644,487 | 9999.99% | 0.02% |
| Aug. 12, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 99 | $30.01 | 51,487.0000 | 72,644,487 | 0.19% | 0.00% |
| Aug. 12, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 101 | $30.01 | 66,704.0000 | 72,644,487 | 0.15% | 0.00% |
| Aug. 13, 2024 | JONES EVAN/ FA | Director | M | Common Stock | 8486 | $10.41 | 59,973.0000 | 72,644,487 | 16.48% | 0.01% |
| Aug. 13, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 2931 | $31.19 | 57,042.0000 | 72,644,487 | 4.89% | 0.00% |
| Aug. 13, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 16838 | $32.36 | 40,204.0000 | 72,644,487 | 29.52% | 0.02% |
| Aug. 13, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 688 | $32.77 | 39,516.0000 | 72,644,487 | 1.71% | 0.00% |
| Aug. 13, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 3869 | $31.19 | 62,835.0000 | 72,644,487 | 5.80% | 0.01% |
| Aug. 13, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 22407 | $32.36 | 40,428.0000 | 72,644,487 | 35.66% | 0.03% |
| Aug. 13, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 912 | $32.77 | 39,516.0000 | 72,644,487 | 2.26% | 0.00% |
| Aug. 13, 2024 | JONES EVAN/ FA | Director | M | Stock Option (right to buy) | 8486 | $0.00 | 0.0000 | 72,644,487 | 100.00% | 0.01% |
| Aug. 7, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 1965 | $30.32 | 80,353.0000 | 72,644,487 | 2.39% | 0.00% |
| Aug. 9, 2024 | JONES EVAN/ FA | Director | M | Common Stock | 300 | $10.41 | 79,907.0000 | 72,644,487 | 0.38% | 0.00% |
| Aug. 9, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 1032 | $30.03 | 78,875.0000 | 72,644,487 | 1.29% | 0.00% |
| Aug. 9, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 746 | $30.03 | 78,875.0000 | 72,644,487 | 0.94% | 0.00% |
| Aug. 9, 2024 | JONES EVAN/ FA | Director | M | Stock Option (right to buy) | 300 | $0.00 | 8,486.0000 | 72,644,487 | 3.41% | 0.00% |
| Aug. 7, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 3143 | $30.32 | 80,353.0000 | 72,644,487 | 3.76% | 0.00% |
| Aug. 7, 2024 | Holstein Jens | Director | S | Common Stock | 2500 | $30.00 | 27,878.0000 | 72,644,487 | 8.23% | 0.00% |
| Aug. 7, 2024 | JONES EVAN/ FA | Director | M | Stock Option (right to buy) | 1214 | $0.00 | 8,786.0000 | 72,644,487 | 12.14% | 0.00% |
| Aug. 7, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 5108 | $30.32 | 80,353.0000 | 72,644,487 | 5.98% | 0.01% |
| Aug. 7, 2024 | JONES EVAN/ FA | Director | M | Common Stock | 1214 | $10.41 | 85,461.0000 | 72,644,487 | 1.44% | 0.00% |
| Aug. 7, 2024 | Holstein Jens | Director | S | Common Stock | 2500 | $28.00 | 30,378.0000 | 72,644,487 | 7.60% | 0.00% |
| July 16, 2024 | Holstein Jens | Director | S | Common Stock | 2500 | $24.00 | 35,378.0000 | 72,644,487 | 6.60% | 0.00% |
| July 16, 2024 | EASTHAM KARIN | Director | S | Common Stock | 7500 | $25.00 | 33,228.0000 | 72,644,487 | 18.41% | 0.01% |
| July 16, 2024 | Leite John | Chief Commercial Officer-CLIA | S | Common Stock | 1277 | $25.00 | 82,968.0000 | 72,644,487 | 1.52% | 0.00% |
| July 16, 2024 | Holstein Jens | Director | S | Common Stock | 2500 | $25.00 | 32,878.0000 | 72,644,487 | 7.07% | 0.00% |
| June 13, 2024 | EASTHAM KARIN | Director | A | Common Stock | 11473 | $0.00 | 40,728.0000 | 72,644,487 | 39.22% | 0.02% |
| June 13, 2024 | JONES EVAN/ FA | Director | A | Common Stock | 11473 | $0.00 | 84,247.0000 | 72,644,487 | 15.77% | 0.02% |
| June 13, 2024 | Barr Eliav | Director | A | Common Stock | 11473 | $0.00 | 41,868.0000 | 72,644,487 | 37.75% | 0.02% |
| June 13, 2024 | Holstein Jens | Director | A | Common Stock | 11473 | $0.00 | 37,878.0000 | 72,644,487 | 43.45% | 0.02% |
| June 13, 2024 | Bhanji Muna | Director | A | Common Stock | 11473 | $0.00 | 34,578.0000 | 72,644,487 | 49.66% | 0.02% |
| June 13, 2024 | EPSTEIN ROBERT S | Director | A | Common Stock | 11473 | $0.00 | 44,598.0000 | 72,644,487 | 34.64% | 0.02% |
| June 11, 2024 | EASTHAM KARIN | Director | S | Common Stock | 3870 | $20.59 | 29,255.0000 | 72,644,487 | 11.68% | 0.01% |
| June 7, 2024 | EASTHAM KARIN | Director | S | Common Stock | 2500 | $20.97 | 33,125.0000 | 72,644,487 | 7.02% | 0.00% |
| June 10, 2024 | Bhanji Muna | Director | S | Common Stock | 3870 | $20.32 | 23,105.0000 | 72,644,487 | 14.35% | 0.01% |
| June 7, 2024 | EASTHAM KARIN | Director | M | Common Stock | 2500 | $10.41 | 35,625.0000 | 72,644,487 | 7.55% | 0.00% |
| June 7, 2024 | EASTHAM KARIN | Director | M | Stock Option (right to buy) | 2500 | $0.00 | 7,500.0000 | 72,644,487 | 25.00% | 0.00% |
| June 2, 2024 | Wygant Jonathan | VP, Chief Accounting Officer | F | Common Stock | 1087 | $20.75 | 47,971.0000 | 72,644,487 | 2.22% | 0.00% |
| June 2, 2024 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 3462 | $20.75 | 143,240.0000 | 72,644,487 | 2.36% | 0.00% |
| June 2, 2024 | McGuire Annie | SVP, General Counsel | F | Common Stock | 1919 | $20.75 | 95,406.0000 | 72,644,487 | 1.97% | 0.00% |
| June 2, 2024 | Stapley Marc | Chief Executive Officer | F | Common Stock | 5746 | $20.75 | 323,994.0000 | 72,644,487 | 1.74% | 0.01% |
| June 2, 2024 | Leite John | Chief Commercial Officer-CLIA | F | Common Stock | 1314 | $20.75 | 84,245.0000 | 72,644,487 | 1.54% | 0.00% |
| May 28, 2024 | Bhanji Muna | Director | S | Common Stock | 1539 | $21.00 | 26,975.0000 | 72,644,487 | 5.40% | 0.00% |
| April 1, 2024 | EASTHAM KARIN | Director | M | Common Stock | 10000 | $13.19 | 43,125.0000 | 72,644,487 | 30.19% | 0.01% |
| April 1, 2024 | EASTHAM KARIN | Director | S | Common Stock | 10000 | $21.65 | 33,125.0000 | 72,644,487 | 23.19% | 0.01% |
| April 1, 2024 | EASTHAM KARIN | Director | M | Stock Option (right to buy) | 10000 | $13.19 | 0.0000 | 72,644,487 | 100.00% | 0.01% |
| March 15, 2024 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 2189 | $21.10 | 146,702.0000 | 72,644,487 | 1.47% | 0.00% |
| March 15, 2024 | Stapley Marc | Chief Executive Officer | A | Common Stock | 11780 | $0.00 | 335,711.0000 | 72,644,487 | 3.64% | 0.02% |
| March 15, 2024 | Stapley Marc | Chief Executive Officer | F | Common Stock | 5971 | $21.10 | 329,740.0000 | 72,644,487 | 1.78% | 0.01% |
| March 15, 2024 | Chambers Rebecca | Chief Financial Officer | A | Common Stock | 4318 | $0.00 | 148,891.0000 | 72,644,487 | 2.99% | 0.01% |
| March 6, 2024 | Wygant Jonathan | VP, Chief Accounting Officer | A | Common Stock | 23942 | $0.00 | 49,058.0000 | 72,644,487 | 95.33% | 0.03% |
| March 6, 2024 | Febbo Phillip G. | Chief Scientific & Med Officer | A | Common Stock | 39904 | $0.00 | 93,086.0000 | 72,644,487 | 75.03% | 0.05% |
| March 6, 2024 | Chambers Rebecca | Chief Financial Officer | A | Common Stock | 59856 | $0.00 | 144,573.0000 | 72,644,487 | 70.65% | 0.08% |
| March 6, 2024 | Stapley Marc | Chief Executive Officer | A | Common Stock | 114724 | $0.00 | 323,931.0000 | 72,644,487 | 54.84% | 0.16% |
| March 6, 2024 | Leite John | Chief Commercial Officer-CLIA | A | Common Stock | 49880 | $0.00 | 85,559.0000 | 72,644,487 | 139.80% | 0.07% |
| March 6, 2024 | McGuire Annie | SVP, General Counsel | A | Common Stock | 49880 | $0.00 | 97,325.0000 | 72,644,487 | 105.13% | 0.07% |
| March 2, 2024 | Leite John | Chief Commercial Officer-CLIA | F | Common Stock | 3008 | $24.00 | 35,679.0000 | 72,644,487 | 7.78% | 0.00% |
| March 2, 2024 | McGuire Annie | SVP, General Counsel | F | Common Stock | 4347 | $24.00 | 47,445.0000 | 72,644,487 | 8.39% | 0.01% |
| March 2, 2024 | Wygant Jonathan | VP, Chief Accounting Officer | F | Common Stock | 2337 | $24.00 | 25,116.0000 | 72,644,487 | 8.51% | 0.00% |
| March 1, 2024 | JONES EVAN/ FA | Director | M | Common Stock | 10000 | $13.19 | 82,774.0000 | 72,644,487 | 13.74% | 0.01% |
| March 1, 2024 | JONES EVAN/ FA | Director | S | Common Stock | 10000 | $24.36 | 72,774.0000 | 72,644,487 | 12.08% | 0.01% |
| March 1, 2024 | JONES EVAN/ FA | Director | M | Stock Option (right to buy) | 10000 | $13.19 | 0.0000 | 72,644,487 | 100.00% | 0.01% |
| March 2, 2024 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 6112 | $24.00 | 84,717.0000 | 72,644,487 | 6.73% | 0.01% |
| March 2, 2024 | Stapley Marc | Chief Executive Officer | F | Common Stock | 13286 | $24.00 | 209,207.0000 | 72,644,487 | 5.97% | 0.02% |
| Dec. 2, 2023 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 1800 | $26.54 | 90,829.0000 | 71,549,204 | 1.94% | 0.00% |
| Dec. 2, 2023 | McGuire Annie | SVP, General Counsel | F | Common Stock | 803 | $26.54 | 51,792.0000 | 71,549,204 | 1.53% | 0.00% |
| Dec. 2, 2023 | Wygant Jonathan | VP, Chief Accounting Officer | F | Common Stock | 507 | $26.54 | 27,020.0000 | 71,549,204 | 1.84% | 0.00% |
| Dec. 2, 2023 | Stapley Marc | Chief Executive Officer | F | Common Stock | 3203 | $26.54 | 221,882.0000 | 71,549,204 | 1.42% | 0.00% |
| Dec. 2, 2023 | Leite John | Chief Commercial Officer-CLIA | F | Common Stock | 556 | $26.54 | 38,687.0000 | 71,549,204 | 1.42% | 0.00% |
| Oct. 2, 2023 | Febbo Phillip G. | Chief Scientific & Med Officer | A | Stock Option (right to buy) | 85858 | $0.00 | 85,858.0000 | 71,549,204 | 9999.99% | 0.12% |
| Oct. 2, 2023 | Febbo Phillip G. | Chief Scientific & Med Officer | A | Common Stock | 53182 | $0.00 | 53,182.0000 | 71,549,204 | 9999.99% | 0.07% |
| Sept. 2, 2023 | Leite John | Chief Commercial Officer-CLIA | F | Common Stock | 2222 | $26.70 | 39,243.0000 | 71,549,204 | 5.36% | 0.00% |
| Sept. 2, 2023 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 3652 | $26.70 | 92,629.0000 | 71,549,204 | 3.79% | 0.01% |
| Sept. 2, 2023 | Wygant Jonathan | VP, Chief Accounting Officer | F | Common Stock | 1247 | $26.70 | 27,527.0000 | 71,549,204 | 4.33% | 0.00% |
| Sept. 2, 2023 | Stapley Marc | Chief Executive Officer | F | Common Stock | 3204 | $26.70 | 225,085.0000 | 71,549,204 | 1.40% | 0.00% |
| Sept. 2, 2023 | McGuire Annie | SVP, General Counsel | F | Common Stock | 1729 | $26.70 | 52,595.0000 | 71,549,204 | 3.18% | 0.00% |
| July 19, 2023 | JONES EVAN/ FA | Director | S | Common Stock | 3090 | $30.17 | 72,774.0000 | 71,549,204 | 4.07% | 0.00% |
| July 19, 2023 | JONES EVAN/ FA | Director | S | Common Stock | 838 | $30.14 | 72,774.0000 | 71,549,204 | 1.14% | 0.00% |
| July 17, 2023 | BISHOP JOHN L | Director | S | Common Stock | 10000 | $30.00 | 33,125.0000 | 71,549,204 | 23.19% | 0.01% |
| July 17, 2023 | BISHOP JOHN L | Director | M | Common Stock | 10000 | $6.37 | 43,125.0000 | 71,549,204 | 30.19% | 0.01% |
| July 18, 2023 | BISHOP JOHN L | Director | S | Common Stock | 10000 | $30.50 | 33,125.0000 | 71,549,204 | 23.19% | 0.01% |
| July 17, 2023 | BISHOP JOHN L | Director | M | Stock Option (right to buy) | 10000 | $0.00 | 25,000.0000 | 71,549,204 | 28.57% | 0.01% |
| July 17, 2023 | JONES EVAN/ FA | Director | S | Common Stock | 19095 | $30.07 | 79,026.0000 | 71,549,204 | 19.46% | 0.03% |
| July 17, 2023 | JONES EVAN/ FA | Director | S | Common Stock | 23949 | $30.07 | 84,143.0000 | 71,549,204 | 22.16% | 0.03% |
| July 18, 2023 | JONES EVAN/ FA | Director | S | Common Stock | 2324 | $30.16 | 76,702.0000 | 71,549,204 | 2.94% | 0.00% |
| July 18, 2023 | JONES EVAN/ FA | Director | S | Common Stock | 7441 | $30.19 | 76,702.0000 | 71,549,204 | 8.84% | 0.01% |
| July 18, 2023 | BISHOP JOHN L | Director | M | Stock Option (right to buy) | 10000 | $0.00 | 15,000.0000 | 71,549,204 | 40.00% | 0.01% |
| July 18, 2023 | BISHOP JOHN L | Director | M | Common Stock | 10000 | $6.37 | 43,125.0000 | 71,549,204 | 30.19% | 0.01% |
| June 16, 2023 | Bhanji Muna | Director | S | Common Stock | 5793 | $26.42 | 28,614.0000 | 71,549,204 | 16.84% | 0.01% |
| June 16, 2023 | Bhanji Muna | Director | S | Common Stock | 100 | $27.09 | 28,514.0000 | 71,549,204 | 0.35% | 0.00% |
| June 9, 2023 | EASTHAM KARIN | Director | A | Common Stock | 9674 | $0.00 | 33,125.0000 | 71,549,204 | 41.25% | 0.01% |
| June 9, 2023 | BISHOP JOHN L | Director | A | Common Stock | 9674 | $0.00 | 33,125.0000 | 71,549,204 | 41.25% | 0.01% |
| June 9, 2023 | JONES EVAN/ FA | Director | A | Common Stock | 9674 | $0.00 | 129,511.0000 | 71,549,204 | 8.07% | 0.01% |
| June 9, 2023 | Holstein Jens | Director | A | Common Stock | 9674 | $0.00 | 26,405.0000 | 71,549,204 | 57.82% | 0.01% |
| June 9, 2023 | Bhanji Muna | Director | A | Common Stock | 9674 | $0.00 | 34,407.0000 | 71,549,204 | 39.11% | 0.01% |
| June 9, 2023 | EPSTEIN ROBERT S | Director | A | Common Stock | 9674 | $0.00 | 33,125.0000 | 71,549,204 | 41.25% | 0.01% |
| June 9, 2023 | Barr Eliav | Director | A | Common Stock | 9674 | $0.00 | 30,395.0000 | 71,549,204 | 46.69% | 0.01% |
| June 2, 2023 | Wygant Jonathan | VP, Chief Accounting Officer | F | Common Stock | 260 | $26.72 | 28,354.0000 | 71,549,204 | 0.91% | 0.00% |
| June 2, 2023 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 1183 | $26.72 | 95,754.0000 | 71,549,204 | 1.22% | 0.00% |
| June 2, 2023 | Stapley Marc | Chief Executive Officer | F | Common Stock | 3203 | $26.72 | 227,696.0000 | 71,549,204 | 1.39% | 0.00% |
| June 2, 2023 | Anderson Bonnie H | Director | F | Common Stock | 1304 | $26.72 | 176,177.0000 | 71,549,204 | 0.73% | 0.00% |
| June 2, 2023 | McGuire Annie | SVP, General Counsel | F | Common Stock | 494 | $26.72 | 54,324.0000 | 71,549,204 | 0.90% | 0.00% |
| May 30, 2023 | Bhanji Muna | Director | S | Common Stock | 1539 | $25.91 | 24,733.0000 | 71,549,204 | 5.86% | 0.00% |
| April 14, 2023 | Anderson Bonnie H | Director | M | Stock Option (right to buy) | 34000 | $0.00 | 34,117.0000 | 71,549,204 | 49.91% | 0.05% |
| April 14, 2023 | Anderson Bonnie H | Director | M | Common Stock | 34000 | $5.61 | 211,481.0000 | 71,549,204 | 19.16% | 0.05% |
| April 14, 2023 | Anderson Bonnie H | Director | S | Common Stock | 34000 | $22.04 | 177,481.0000 | 71,549,204 | 16.08% | 0.05% |
| March 16, 2023 | EASTHAM KARIN | Director | M | Common Stock | 18750 | $12.12 | 42,201.0000 | 71,549,204 | 79.95% | 0.03% |
| March 16, 2023 | EASTHAM KARIN | Director | M | Stock Option (right to buy) | 18750 | $0.00 | 0.0000 | 71,549,204 | 100.00% | 0.03% |
| March 16, 2023 | EASTHAM KARIN | Director | S | Common Stock | 18750 | $22.78 | 23,451.0000 | 71,549,204 | 44.43% | 0.03% |
| March 15, 2023 | Anderson Bonnie H | Director | M | Common Stock | 34000 | $5.61 | 211,481.0000 | 71,549,204 | 19.16% | 0.05% |
| March 15, 2023 | Anderson Bonnie H | Director | S | Common Stock | 34000 | $22.76 | 177,481.0000 | 71,549,204 | 16.08% | 0.05% |
| March 15, 2023 | Anderson Bonnie H | Director | M | Stock Option (right to buy) | 34000 | $0.00 | 68,117.0000 | 71,549,204 | 33.30% | 0.05% |
| March 6, 2023 | Stapley Marc | Chief Executive Officer | A | Common Stock | 78044 | $0.00 | 230,899.0000 | 71,549,204 | 51.06% | 0.11% |
| March 6, 2023 | Stapley Marc | Chief Executive Officer | A | Stock Option (right to buy) | 128869 | $0.00 | 128,869.0000 | 71,549,204 | 9999.99% | 0.18% |
| March 6, 2023 | McGuire Annie | SVP, General Counsel | A | Common Stock | 23413 | $0.00 | 54,818.0000 | 71,549,204 | 74.55% | 0.03% |
| March 6, 2023 | McGuire Annie | SVP, General Counsel | A | Stock Option (right to buy) | 38660 | $0.00 | 38,660.0000 | 71,549,204 | 9999.99% | 0.05% |
| March 6, 2023 | Wygant Jonathan | VP, Chief Accounting Officer | A | Common Stock | 8868 | $0.00 | 28,614.0000 | 71,549,204 | 44.91% | 0.01% |
| March 6, 2023 | Wygant Jonathan | VP, Chief Accounting Officer | A | Stock Option (right to buy) | 14213 | $0.00 | 14,213.0000 | 71,549,204 | 9999.99% | 0.02% |
| March 6, 2023 | Chambers Rebecca | Chief Financial Officer | A | Common Stock | 26014 | $0.00 | 96,937.0000 | 71,549,204 | 36.68% | 0.04% |
| March 6, 2023 | Chambers Rebecca | Chief Financial Officer | A | Stock Option (right to buy) | 42956 | $0.00 | 42,956.0000 | 71,549,204 | 9999.99% | 0.06% |
| March 2, 2023 | Chambers Rebecca | Chief Financial Officer | F | Common Stock | 2726 | $24.10 | 70,923.0000 | 71,549,204 | 3.70% | 0.00% |
| March 2, 2023 | Stapley Marc | Chief Executive Officer | F | Common Stock | 6029 | $24.10 | 152,855.0000 | 71,549,204 | 3.79% | 0.01% |
| March 2, 2023 | Anderson Bonnie H | Director | F | Common Stock | 8994 | $24.10 | 177,481.0000 | 71,549,204 | 4.82% | 0.01% |
| March 2, 2023 | Wygant Jonathan | VP, Chief Accounting Officer | F | Common Stock | 1224 | $24.10 | 19,746.0000 | 71,549,204 | 5.84% | 0.00% |
| March 2, 2023 | McGuire Annie | SVP, General Counsel | F | Common Stock | 2152 | $24.10 | 31,405.0000 | 71,549,204 | 6.41% | 0.00% |
| Feb. 28, 2023 | EASTHAM KARIN | Director | M | Common Stock | 10000 | $12.12 | 33,451.0000 | 71,549,204 | 42.64% | 0.01% |
| Feb. 28, 2023 | EASTHAM KARIN | Director | S | Common Stock | 10000 | $25.00 | 23,451.0000 | 71,549,204 | 29.89% | 0.01% |
| Feb. 28, 2023 | EASTHAM KARIN | Director | M | Stock Option (right to buy) | 10000 | $0.00 | 18,750.0000 | 71,549,204 | 34.78% | 0.01% |
| Jan. 17, 2023 | Anderson Bonnie H | Director | M | Common Stock | 34000 | $5.61 | 220,475.0000 | 71,549,204 | 18.23% | 0.05% |
| Jan. 17, 2023 | Anderson Bonnie H | Director | S | Common Stock | 29506 | $26.30 | 190,969.0000 | 71,549,204 | 13.38% | 0.04% |
| Jan. 17, 2023 | Anderson Bonnie H | Director | S | Common Stock | 4494 | $26.64 | 186,475.0000 | 71,549,204 | 2.35% | 0.01% |
| Jan. 17, 2023 | Anderson Bonnie H | Director | M | Stock Option (right to buy) | 34000 | $0.00 | 102,117.0000 | 71,549,204 | 24.98% | 0.05% |
| Jan. 11, 2023 | Anderson Bonnie H | Director | M | Common Stock | 63247 | $14.34 | 249,722.0000 | 71,549,204 | 33.92% | 0.09% |
| Jan. 11, 2023 | Anderson Bonnie H | Director | S | Common Stock | 63247 | $25.13 | 186,475.0000 | 71,549,204 | 25.33% | 0.09% |
| Jan. 11, 2023 | Anderson Bonnie H | Director | M | Stock Option (right to buy) | 63247 | $0.00 | 26,753.0000 | 71,549,204 | 70.27% | 0.09% |